Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study

Journal:

Blood

Published:

2026-06-04

DOI:

10.1182/blood.2025030120

Affiliations:

23

Authors:

21

Go to article

Institutions	Authors	Share
University Hospital Ostrava, OSU, Czech Republic	2.000000	0.10
Sanofi, France	2.000000	0.10
Sanofi US, United States of America (USA)	2.000000	0.10
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.05
Centre d’Investigation Clinique de Poitiers (CIC de Poitiers), France	1.000000	0.05
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER), France	1.000000	0.05
Japanese Red Cross Medical Center, Japan	1.000000	0.05
Maria Sklodowska-Curie National Research Institute of Oncology, Poland	1.000000	0.05
Botkin Municipal Clinic, Russia	1.000000	0.05
University Hospital Tübingen (UKT), Uni Tübingen, Germany	1.000000	0.05
Istanbul University, Turkey	1.000000	0.05
Copernicus Memorial Hospital, Poland	1.000000	0.05
Heidelberg University Hospital at Medical Faculty Heidelberg, Uni Heidelberg, Germany	1.000000	0.05
University of California, San Francisco (UCSF), United States of America (USA)	1.000000	0.05
Hôtel-Dieu de Paris, France	1.000000	0.05
National and Kapodistrian University of Athens (UOA), Greece	0.500000	0.02
Korea University, South Korea	0.500000	0.02
General University Hospital in Prague, Czech Republic	0.500000	0.02
Charles University (CU), Czech Republic	0.500000	0.02
Saint Antoine Hospital, France	0.333333	0.02
Sorbonne University, France	0.333333	0.02
National Institute for Health and Medical Research (INSERM), France	0.333333	0.02